Savara Inc

Savara Inc. Gets FDA Extension for Molgramostim Review

LANGHORNE, Pa., April 15, 2026 Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced that the...

By cGxPwire Editor
April 16, 2026

Bio-Pharma

Savara Raises $149.5M to Advance Rare Lung Therapeutic Program

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...

By cGxPwire Editor
November 2, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Savara Inc

Savara Inc. Gets FDA Extension for Molgramostim Review

Savara Raises $149.5M to Advance Rare Lung Therapeutic Program